Osteogenic capacity of the sinus membrane following maxillary sinus augmentation procedures: A systematic review
A systematic review of preclinical studies found inconsistent evidence regarding the sinus membrane's contribution to new bone formation following maxillary sinus augmentation, though the membrane's pluripotent mesenchymal cells show potential for osteogenic differentiation, particularly when stimulated by recombinant human bone morphogenic proteins.
Dr. Theo Katsaros
Periodontist
Table of contents
Share
Background & clinical context
Maxillary sinus augmentation is one of the most commonly performed procedures to enable implant placement in the posterior maxilla where bone volume is insufficient.
The Schneiderian membrane is elevated during these procedures to create space for bone grafting material. While its primary role is structural, a longstanding and clinically relevant question has been whether the sinus membrane itself actively contributes to new bone formation.
If the sinus membrane has meaningful osteogenic potential, it could influence decisions around graft selection, membrane management during perforation, and even whether grafting is necessary in certain clinical scenarios. This systematic review set out to consolidate the available evidence on the membrane's bone-forming capacity and the effect of locally delivered recombinant human bone morphogenic proteins (rhBMPs) on that potential.
Key findings
Osteogenic potential of the sinus membrane
Of the 26 preclinical studies included, 17 directly assessed the membrane's osteogenic capacity without rhBMP enhancement. Results were evenly split and inconclusive.
Finding | No. of studies | Interpretation |
|---|---|---|
Supported osteogenic potential of the sinus membrane | 9 studies | Membrane cells demonstrated capacity to differentiate and contribute to new bone formation near the membrane |
Found no evidence of osteogenicity from the sinus membrane | 8 studies | New bone formation in proximity to the membrane was not attributed to membrane-derived cells |
Assessed rhBMP local delivery effect on membrane | 9 studies | Majority reported enhanced new bone formation in the sinus membrane region with rhBMP application |
A critical gap in the evidence
No clinical studies were identified that met inclusion criteria. All 26 included studies were preclinical (animal) studies. This means the biological findings cannot be directly extrapolated to human clinical outcomes without further research.
What the biology tells us
The review confirms that the sinus membrane contains pluripotent mesenchymal cells; cells with the biological machinery to differentiate into bone-forming osteoblasts. This is the mechanistic basis for the osteogenic potential hypothesis.
However, having the capacity for bone formation and reliably contributing to it under clinical conditions are different things. The preclinical data does not consistently demonstrate that this potential translates into significant new bone formation following standard sinus augmentation procedures.
The rhBMP findings are more directionally consistent: local delivery of recombinant bone morphogenic proteins to the sinus membrane region appears to upregulate its bone-forming activity in the majority of studies that assessed this.
This suggests that while the membrane's intrinsic osteogenic activity may be limited under normal conditions, it can be stimulated by appropriate biological signals.
Summary of evidence
Intrinsic osteogenicity
Biologically plausible but not consistently demonstrated — evidence evenly split
rhBMP enhancement
Majority of studies show improved bone formation with local rhBMP delivery
Clinical evidence
No qualifying human clinical studies identified — all evidence is preclinical
Clinical bottom line
For the practitioner
The sinus membrane should be understood as a biologically active structure with osteogenic potential rather than a passive barrier. Its mesenchymal cell content gives it the theoretical capacity to contribute to new bone formation.
However, the current evidence does not yet support modifying clinical protocols based on this potential alone. The more consistent signal is that rhBMP delivery to the membrane region amplifies its bone-forming activity, which may become clinically relevant as biologic adjuncts continue to evolve in implant-site development.
